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A precondition for understanding if-and-when obser-
vations on wet-lab research models can translate to 
patients (and vice versa) is to have a method that en-
ables anticipating how each system at the mechanism 
level will respond to the same or similar new interven-
tion.  A new class of mechanistic, in silico analogues is 
described.  We argue that, although abstract, they en-
able developing that method.  Building an analogue of 
each system within a common framework allows ex-
ploration of how one analogue might undergo (auto-
mated) metamorphosis to become the other.  When 
successful, a concrete mapping is achieved.  We hy-
pothesize that such a mapping is, itself, an analogue of 
a corresponding mapping between the two referent 
systems.  The analogue mapping can help establish 
how targeted aspects of the two referent systems are 
similar and different, at the mechanistic level and, im-
portantly, at the systemic, emergent property level.  
The vision is that the analogues along with the meta-
morphosis method can be improved iteratively as part 
of a rational approach to translational research. 
Introduction
Complex problems often require well-designed, com-
plex solutions.  A pillar of the NIH Roadmap is the 
idea that scientific discoveries must be translated into 
practical applications.  Translation means a rendering 
from one representational system into another; repre-
sentation means a likeness, model, or other [analogue] 
reproduction.  The phrase “from one representational 
system into another” is important for this report be-
cause it suggests a method within a common frame-
work.  There is a large and deep literature on biomedi-
cal ontologies serving as reality representations.1  The 
focus here is somewhat different: it is to present a 
method of building flexible, mechanistic analogue rep-
resentations of related model systems used for re-
search, such as in vitro and in vivo, and then achieving 
an additional method for translating one analogue into 
the other, so that the embedded knowledge can lever-
aged for the benefit of patients.1
46In biomedical research, the representational systems 
typically include specific in vitro models, animal mod-
els, and abstract, “typical” patients exhibiting specific 
disease symptoms.  The phrase translational research 
can imply that one seeks sufficient knowledge to pro-
pound mappings from observations made in vitro to 
those made in animals, and on to those made in pa-
tients (and/or the reverse).  Often, the observations of 
interest are experimental outcomes following specific 
interventions.  Because the systems are complex and at 
times possibly even non-intuitive, mappings between 
them have often proven difficult to establish.  
Toward a Method
Because biomedical wet-lab research models are com-
plex, we can expect most mappings between them to be 
nonlinear and rarely simple.  A mapping requires se-
lecting an aspect of each system on which to focus, and 
then selecting a perspective and means from which to 
view and measure phenotypic attributes.  Identical as-
pects may not exist in the different models.  It may not 
be clear which aspect in one model corresponds to the 
one of interest in another.  Further, practical and ethi-
cal considerations may preclude observing and measur-
ing the systems using the same means or even using the 
same observational perspective.  Navigating these re-
alities can be problematic and that has been one of the 
motivations for increased interest in mostly empirical 
biomarker discovery research 2. 
The development of a new drug (a candidate 
therapeutic intervention) from early in vitro 
observations into a new, approved treatment, when 
successful, is a simple example of successful 
translational research.  The extremely low rate of 
success of that process within the pharmaceutical and 
biotech industries3 is illustrative of our current 
limitations for translating information about one wet-
lab model into useful insight about another, related 
model.  To simplify the discussion that follows, we 
focus on development of new drug treatments as an 
example of translational research.
Occasionally, when translation is successful, it is 
because relationships that exist between the observable 
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model systems have been somewhat straightforward.  
That situation is illustrated in Fig. 1.  Continuing the 
drug development example: in a few cases (e.g., the 
one marked a in Fig. 1A), following dosing with the 
compound being researched, the pharmacological 
attributes and their generative mechanisms may be 
within the area of overlap.  More often (marked b), the 
pharmacological attributes and their generative 
mechanisms do not overlap because aspects of the 
generative mechanisms at the whole system level are 
fundamentally different.  Such differences can occur 
even when specific details (within the generative 
mechanisms) are essentially the same.  Because of the 
complexities involved, coupled with the limits of 
reductionism,4 only recently has effort been invested in
trying specifically to develop and understand mappings 
between systems as in Fig. 1 at the mechanistic level.  
The expanding variety of measurements (omics, 
imaging, etc.) provides the mapping within the 
system’s phenomenal manifold, commensurate with its
environment.  The phenomenal manifold has been the 
primary focus for biomedical informatics and 
ontologies research to date.  It contains the intersection 
of bioinformatics and health informatics.5  Models and 
simulations can also provide mappings6 by virtue of the 
requirement that the model provide a phenomenal 
manifold (of its own) that is acceptably similar to its 
referent.  Such mappings are essential elements of an 
anticipated ontology that would strive to account for 
how one system relates to another.  Absent that, the 
research remains empirical, and the low translational 
success rate experienced by drug developers and basic 
researchers will most likely persist.
How can we develop improved mechanistic mappings 
and thus begin putting in place the essential elements 
of quantitative methods of translational research?  
Consider the following five conditions.  
1. A simple, abstract in silico system, containing ac-
tive and passive components, is offered as a func-
tioning analogue of a particular biological system 
used for experimentation. 
2. A set of measurements of the analogue’s behaviors 
under different conditions (phenotypic attributes) 
is judged by domain experts to be experimentally 
indistinguishable from (acceptably similar to) cor-
responding measurements of the referent system. 
3. The analogue’s components and their observable 
relationships have easily identified, logically con-
sistent counterparts in the biological system. 
4. The mechanisms underlying the analogue system’s 
behaviors are a consequence exclusively of active 
(as opposed to merely reactive) component ac-
tions. 2
475. The analogue’s active components function inde-
pendently of one another (simulated autonomy): 
each uses axioms to determine the action to be 
taken based exclusively on its current state and the 
nature of its immediate, local environment. 
When these five conditions are met, then we can state 
the following.  1) Understanding and predicting 
mechanisms in the referent is facilitated by studying 
the mechanisms in the analogue.  2) Studying the be-
havioral axioms of the analogue components facilitates 
exploration of their biological counterparts: a set of 
important principles of operation relied upon by the 
biological functional units.  
Figure 1: Relationships between the phenotypes of 
different model systems.  Each circle represents a set 
of relevant, measurable phenotypic attributes, viewed 
from a common perspective, of three different systems 
(an in-vitro, wet-lab model, an animal model, and 
patients), along with their generative mechanisms.  An 
example of attributes is measurable pharmacological 
properties following administration of the same drug.  
The in vitro system is a functioning analogue of 
targeted aspects of an animal model, which, in turn, is 
a model of certain aspects of a disease.  A: The area of 
intersection among the three sets (marked a) represents 
a situation in which the pharmacological attributes and 
generative mechanisms in all three systems are similar.  
In such cases, extrapolation and thus translation from 
in vitro to patients is reasonably straightforward.  
However, the pharmacological attributes and/or their 
generative mechanisms can have fundamental 
differences (marked b); although aspects of each 
system are purposefully related, there is no logically 
consistent overlap in the full set of phenotypic 
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phenotypic attributes of an in silico system are shown.  
Assume that it is a validated, abstract, but 
mechanistically realistic analogue (as in Fig. 2) of the 
in vitro system.  Area of overlap: measurable 
properties of the analogue during execution 
(simulation) are experimentally indistinguishable from 
corresponding measures of the wet-lab system.  C: 
After multiple rounds of revision and validation, “In 
Silico A” has evolved to become “In Silico B.”  The 
larger area of overlap means that a larger set of the 
analogue’s relevant phenotypic attributes (and 
generative mechanisms) has been judged similar to 
wet-lab counterparts.  Consequently, “In Silico B” 
embodies more of what we think we know about the in 
vitro system: it has become an informatics tool suitable 
for experimentation.  D: Assume that a different in 
silico system—“In Silico C”—has been built using 
software components similar to those used by “In 
Silico B.”  Further, it has been instantiated and 
validated within the same framework as “In Silico B”; 
the two analogues may use some of the same 
components but having different parameterizations.  
An automated method of metamorphosis, illustrated in 
Fig. 3, can be developed to change “In Silico B” into 
“In Silico C” and vise versa.  The features lost and 
gained in that metamorphosis can stand as a hypothesis 
of what can and cannot be translated from in vitro to 
animal model. 
To date, such principles have arrived piecemeal by in-
duction following experimentation.  Achieving and re-
fining analogues like that described above offers a sci-
entific, experimental approach to discovering cohesive 
sets of principles.  A cohesive set operating principles 
(as distinct from isolated principles) can provide a 
framework into which more detailed, multilevel (cellu-
lar, subcellular, molecular, etc.) information can be 
connected directly to system level phenotype.
The above conditions suggest an approach7.  We can 
begin by using available tools and semi-autonomous 
components8-10 to build a functioning in silico system 
that is an analogue, a non-deterministic representation, 
that exhibits a narrowly circumscribed set of pheno-
typic attributes.  Such a model will have a phenotype
of its own, one that overlaps somewhat with that of the 
referent in vitro system, as shown in Fig. 1B (condition 
2).  The in silico white blood cells (ISWBC)11 and 
agent-based inflammatory cells12 are early examples.  
The best way to understand how particular system be-
haviors emerge is to build a separate, independent, 
simpler system that exhibits some of those same behav-
iors (condition 1).  Note: that idea, motivated by the 
reductionist paradigm, has in turn motivated the crea-3
48tion and development of many of the in vitro systems 
currently used in biomedical research today.  However, 
reductionist research methods may not succeed in de-
scribing system-level properties of living organisms13.  
The envisioned, in silico analogue in Fig. 2 is concep-
tually different from the precise mathematical descrip-
tions of hypothesized mechanisms and the behaviors 
that characterize the majority of current, inductive, 
computational biomedical models. 
Once we have an in silico analogue comprised of 
locally interacting semi-autonomous components 
(mechanisms) that cause systemic events and be-
haviors, we can hypothesize mappings to a referent 
biological system at two or more levels, as illustrated 
in Fig. 2.  
Figure 2. Illustration of relationships between the 
mechanisms and components within an in silico 
analogue (example: in silico white blood cells11: 
ISWBC) and the referent in vitro or in vivo counter-
parts.  When there is acceptable, temporal and dynamic 
similarity at the observational level (in silico 
observations and data validate against referent 
observations and data), then we can hypothesize that 
the in silico behaviors have biological counterparts (an 
iteratively concretizable mapping exists).  Because 
those behaviors are caused by in silico mechanisms, we 
can also hypothesize that they too have biological 
counterparts.  The in silico analogue stands as an 
instantiated, temporal, dynamic, and adaptive theory 
for how the biological system works.
Driven by coordinated, iterative, wet-lab and in silico 
experimental observations, the foundational analogue 
can be iteratively revised and validated with the aim of 
improving its mapping to the in vitro system, as 
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silico components can map to biological components, 
and at the systems level, in silico behaviors can map to 
in vitro behaviors.  The ultimate goal of this process is 
to develop methods and hypotheses that support a 
metamorphosis of one validated in silico analogue into 
another (Figs. 1D and 3).  A validated in silico 
analogue of an in vitro model that can change into a 
validated in silico analogue of a related, in vivo model 
stands as an instantiated hypotheses for corresponding 
mappings between the in vitro and in vivo systems.  In 
silico, the method is extensible to patients, because 
some experimental in vitro systems serve as analogues 
of aspects of disease, e.g., when material form a patient 
becomes a component of the in vitro system14.
Figure 3. Mapping between in vitro and in vivo model 
systems.  An in vitro model serves as an abstract 
analogue of an in vivo model, as in Fig. 1B.  There is 
uncertainty about the degree to which observable 
consequences of interventions made in vitro can be 
used to predict the consequences of comparable 
interventions in vivo, because knowledge of how the in 
vitro model maps to the in vivo model is too vague.  
Assume that a validated analogue (B) exists, as in Fig. 
2, of the in vitro system, and that a validated analogue 
(C) also exists of the in vivo system.  Both analogues 
exist within the same framework.  A method is 
developed to structurally change analogue B into 
analogue C, and vice versa.  That metamorphosis 
stands as a working, testable hypothesis of how an 
experimental intervention on the in vitro system 
translates to expected consequences in the in vivo 
system.  In silico, we know what is gained and lost in 
translation (during the metamorphosis), including 
translational heterogeneity.  Additionally, we can 
acknowledge (and in some cases simulate) translation 
error and ambiguity.  We can use the representation of 
that insight to anticipate counterparts for the biological 
systems.  Further, we can imagine extending the 
relationship to patients.  When that is done, the silico 
analogues become the current best ontology for what 
does and does not translate.4
49The plan for achieving translation mappings as 
depicted in Figs. 2 and 3 cannot be achieved using 
traditional, inductive models as analogues: although 
that class of models works well for precise prediction 
in a well-defined context, inductive models lack the 
conditions listed above that we argue are essential for 
achieving analogues of the type illustrated in Fig. 2.  
Merging lessons from the literature with those learned 
during the evolution of three projects11, 15-17, along with 
identifiable requirements that must be met in order to 
achieve analogues that can be extended to include the 
temporal features implied in Fig. 3, we identify five 
capabilities that the envisioned analogues should 
exhibit.  
1. Transparency: in silico analogues must be trans-
parent.  Component details and their interactions 
need to be visualizable, measurable, and accessi-
ble to intervention as the simulation progresses.  
2. Articulation: It must be easy to join, disconnect, 
and replace in silico components within and be-
tween levels, and within the simulated experimen-
tal context: i.e., the components articulate.  
3. Granulari ty : it should be relatively simple to 
change usage and assumptions, or increase or de-
crease detail (unplug a component and replace it 
with one that is more or less complicated, having 
finer or coarser granularity) in order to meet the 
particular needs of an in silico experiment, without 
requiring significant re-engineering of the in silico 
system. 
4. Reusability: The analogue and its components 
need to be designed to be reusable for simulating 
behaviors in different experimental conditions.  
5. Discrete interactions: to enable the above capa-
bilities, the analogues in Fig. 3 and their frame-
work must include discrete interactions that ex-
plicitly show relations between components. 
A simulation system that exhibits these five capabilities 
has three advantages.  First, the quantifiable set of 
rules or axioms11, 15-17 that govern their behavior are the 
in silico counterpart of a biological systems principles 
of operation.  The operating principles followed are 
based on local information rather than central control.  
Validation of plausible principles of operation is an 
essential step in building mappings between laboratory 
models and from those models to patients.  Second, 
agent based modeling methods take advantage of the 
principle of emergence.  The temporal interaction of 
adaptive agents allows the resultant dynamics to 
develop within the context of the system as a whole, 
thus preserving aspects of the complexity inherent to 
living systems.  This conservation of complexity is 
thought to be vital in studying the behavior of complex 
systems and understanding what may be vital to 
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modeling is intuitive.  For researchers who are non-
mathematicians, the agent-based paradigm has 
demonstrated its ability to allow easier transfer of their 
domain-specific knowledge into simulations.  As a 
result, analogue engineering is more transparent, and it 
is potentially easier to identify artifacts arising during 
construction. 
Summary
In summary, we have argued that in order to achieve a 
much higher frequency of successful translation of 
basic, biomedical research (bench) findings into 
applications that improve health (bedside), new, in 
silico methods are needed to facilitate the rendering 
from representational systems that live in the research 
domain (in vitro, animals, etc.) into that of patients.  
These methods, we argue, will need to include the use 
of analogue systems capable of producing emergent 
properties analogous to those characteristic of living 
organisms.  With the described class of analogues, we 
can begin to identify if and how observations in a wet-
lab research model may map to expected observations 
in patients.  Without that critical component, potential 
benefits of research will continue to be at risk of 
getting lost in translation from bench to bedside. 
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